4-(N-Alkyl- and -Acyl-amino)-1,2,4-triazole-3-thione Analogs as Metallo-Beta-Lactamase Inhibitors: Impact of 4-Linker on Potency and Spectrum of Inhibition
[en] To fight the increasingly worrying bacterial resistance to antibiotics, the discovery and development of new therapeutics is urgently needed. Here, we report on a new series of 1,2,4-triazole-3-thione compounds as inhibitors of metallo-β-lactamases (MBLs), which represent major resistance determinants to β-lactams, and especially carbapenems, in Gram-negative bacteria. These molecules are stable analogs of 4-amino-1,2,4-triazole-derived Schiff bases, where the hydrazone-like bond has been reduced (hydrazine series) or the 4-amino group has been acylated (hydrazide series); the synthesis and physicochemical properties thereof are described. The inhibitory potency was determined on the most clinically relevant acquired MBLs (IMP-, VIM-, and NDM-types subclass B1 MBLs). When compared with the previously reported hydrazone series, hydrazine but not hydrazide analogs showed similarly potent inhibitory activity on VIM-type enzymes, especially VIM-2 and VIM-4, with Ki values in the micromolar to submicromolar range. One of these showed broad-spectrum inhibition as it also significantly inhibited VIM-1 and NDM-1. Restoration of β-lactam activity in microbiological assays was observed for one selected compound. Finally, the binding to the VIM-2 active site was evaluated by isothermal titration calorimetry and a modeling study explored the effect of the linker structure on the mode of binding with this MBL.
4-(N-Alkyl- and -Acyl-amino)-1,2,4-triazole-3-thione Analogs as Metallo-Beta-Lactamase Inhibitors: Impact of 4-Linker on Potency and Spectrum of Inhibition
Publication date :
2020
Journal title :
Biomolecules
eISSN :
2218-273X
Publisher :
Multidisciplinary Digital Publishing Institute (MDPI), Switzerland
Fernandes, R.; Amador, P.; Prudêncio, C. β-Lactams: Chemical structure, mode of action and mechanisms of resistance. Rev. Med. Microbiol. 2013, 24, 7–17. [CrossRef]
Peterson, E.; Kaur, P. Antibiotic resistance mechanisms in bacteria: Relationships between resistance determinants of antibiotic producers, environmental bacteria, and clinical pathogens. Front. Microbiol. 2018, 9, 2928–2949. [CrossRef] [PubMed]
Silver, L.L. The antibiotic future. In Antibacterials; Fischer, J.F., Mobashery, S., Miller, M.J., Eds.; Springer: Cham, Germany, 2017; Volume 25, pp. 31–67. [CrossRef]
Aslam, B.; Wang, W.; Arshad, M.I.; Khurshid, M.; Muzammil, S.; Rasool, M.H.; Nisar, M.A.; Alvi, R.F.; Aslam, M.A.; Qamar, M.U.; et al. Antibiotic resistance: A rundown of a global crisis. Infect. Drug Resist. 2018, 11, 1645–1658. [CrossRef] [PubMed]
Laws, M.; Shaaban, A.; Rahman, K.M. Antibiotic resistance breakers: Current approaches and future directions. FEMS Microbiol. Rev. 2019, 43, 490–516. [CrossRef]
Review on Antimicrobial Resistance: Tackling Drug-Resistant Infections Globally. Available online: https://amr-review.org/(accessed on 29 November 2019).
Zaman, S.B.; Hussain, M.A.; Nye, R.; Mehta, V.; Mamun, K.T.; Hossain, N. A review on antibiotic resistance: Alarm bells are ringing. Cureus 2017, 9, 1–19. [CrossRef]
Ventola, C.L. The antibiotic resistance crisis. Part 1: Causes and Threats. Pharm. Ther. 2015, 40, 277–283.
Tacconelli, E.; Carrara, E.; Savoldi, A.; Harbarth, S.; Mendelson, M.; Monnet, D.L.; Pulcini, C.; Kahlmeter, G.; Kluytmans, J.; Carmeli, Y.; et al. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 2018, 18, 318–327. [CrossRef]
Worthington, R.J.; Melander, C. Overcoming resistance to β-lactam antibiotics. J. Org. Chem. 2013, 78, 4207–4213. [CrossRef]
Bonomo, R.A. β-Lactamases: A focus on current challenges. Cold Spring Harb. Perspect. Med. 2017, 7, 1–15. [CrossRef]
Bush, K.; Bradford, P.A. Interplay between β-lactamases and new β-lactamase inhibitors. Nat. Rev. Microbiol. 2019, 17, 295–306. [CrossRef]
Mojica, M.F.; Bonomo, R.A.; Fast, W. B1-Metallo-β-lactamases: Where do we stand? Curr. Drug Targets 2016, 17, 1029–1050. [CrossRef] [PubMed]
Linciano, P.; Cendron, L.; Gianquinto, E.; Spyrakis, F.; Tondi, D. Ten years with New Delhi Metallo-β-Lactamase-1 (NDM-1): From structural insights to inhibitor design. ACS Infect. Dis. 2019, 5, 9–34. [CrossRef] [PubMed]
McGeary, R.P.; Dan, D.T.C.; Schenk, G. Progress toward inhibitors of metallo-β-lactamases. Future Med. Chem. 2017, 9, 673–691. [CrossRef] [PubMed]
Liénard, B.M.; Garau, G.; Horsfall, L.; Karsisiotis, A.I.; Damblon, C.; Lassaux, P.; Papamicael, C.; Roberts, G.C.; Galleni, M.; Dideberg, O.; et al. Structural basis for the broad-spectrum inhibition of metallo-β-lactamases by thiols. Org. Biomol. Chem. 2008, 6, 2282–2294. [CrossRef]
Lassaux, P.; Hamel, M.; Gulea, M.; Delbrück, H.; Mercuri, P.S.; Horsfall, L.; Dehareng, D.; Kupper, M.; Frère, J.-M.; Hoffmann, K.; et al. Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-β-lactamases. J. Med. Chem. 2010, 53, 4862–4876. [CrossRef]
Everett, M.; Sprynski, N.; Coelho, A.; Castandet, J.; Bayet, M.; Bougnon, J.; Lozano, C.; Davies, D.T.; Leiris, S.; Zalacain, M.; et al. Discovery of a novel metallo-β-lactamase inhibitor that potentiates meropenem activity against carbapenem-resistant Enterobacteriaceae. Antimicrob. Agents Chemother. 2018, 62, 7–18. [CrossRef]
Leiris, S.; Coelho, A.; Castandet, J.; Bayet, M.; Lozano, C.; Bougnon, J.; Bousquet, J.; Everett, M.; Lemonnier, M.; Sprynski, N.; et al. SAR studies leading to the identification of a novel series of metallo-β-lactamase inhibitors for the treatment of carbapenem-resistant Enterobacteriaceae infections that display efficacy in an animal infection model. ACS Infect. Dis. 2019, 5, 131–140. [CrossRef]
Hecker, S.J.; Reddy, K.R.; Lomovskaya, O.; Griffith, D.C.; Rubio-Aparicio, D.; Nelson, K.; Tsivkovski, R.; Sun, D.; Sabet, M.; Tarazi, Z.; et al. Discovery of cyclic boronic acid QPX7728, an ultra-broad-spectrum inhibitor of serine and metallo-β-lactamases. J. Med. Chem. 2020. [CrossRef]
Docquier, J.-D.; Mangani, S. An update on β-lactamase inhibitor discovery and development. Drug Resist. Update 2018, 36, 13–29. [CrossRef]
González-Bello, C.; Rodríguez, D.; Pernas, M.; Rodríguez, Á.; Colchón, E. β-Lactamase inhibitors to restore the efficacy of antibiotics against superbugs. J. Med. Chem. 2020, 63, 1859–1881. [CrossRef]
Olsen, L.; Jost, S.; Adolph, H.W.; Pettersson, I.; Hemmingsen, L.; Jørgensen, F.S. New leads of metallo-β-lactamase inhibitors from structure-based pharmacophore design. Bioorg. Med. Chem. 2006, 14, 2627–2635. [CrossRef]
Nauton, L.; Kahn, R.; Garau, G.; Hernandez, J.-F.; Dideberg, O. Structural insights into the design of inhibitors for the L1 metallo-β-lactamase from Stenotrophomonas maltophilia. J. Mol. Biol. 2008, 375, 257–269. [CrossRef] [PubMed]
Sevaille, L.; Gavara, L.; Bebrone, C.; De Luca, F.; Nauton, L.; Achard, M.; Mercuri, P.; Tanfoni, S.; Borgianni, L.; Guyon, C.; et al. 1,2,4-Triazole-3-thione compounds as inhibitors of dizinc metallo-β-lactamases. Chem. Med. Chem. 2017, 12, 972–985. [CrossRef] [PubMed]
Kwapien, K.; Damergi, M.; Nader, S.; El Khoury, L.; Hobaika, Z.; Maroun, R.G.; Piquemal, J.-P.; Gavara, L.; Berthomieu, D.; Hernandez, J.-F.; et al. Calibration of 1,2,4-triazole-3-thione, an original Zn-binding group of metallo-β-lactamase inhibitors. Validation of a polarizable MM/MD potential by quantum chemistry. J. Phys. Chem. B 2017, 121, 6295–6312. [CrossRef]
Gavara, L.; Sevaille, L.; De Luca, F.; Mercuri, P.; Bebrone, C.; Feller, G.; Legru, A.; Cerboni, G.; Tanfoni, S.; Baud, D.; et al. 4-Amino-1,2,4-triazole-3-thione-derived Schiff bases as metallo-β-lactamase inhibitors. Eur. J. Med. Chem. under review.
Studier, F.W. Protein production by auto-induction in high density shaking cultures. Protein Expr. Purif. 2005, 41, 207–234. [CrossRef] [PubMed]
Laraki, N.; Franceschini, N.; Rossolini, G.M.; Santucci, P.; Meunier, C.; de Pauw, E.; Amicosante, G.; Frère, J.-M.; Galleni, M. Biochemical characterization of the Pseudomonas aeruginosa 101/1477 metallo-β-lactamase IMP-1 produced by Escherichia coli. Antimicrob. Agents Chemother. 1999, 43, 902–906. [CrossRef] [PubMed]
Docquier, J.-D.; Pantanella, F.; Giuliani, F.; Thaller, M.C.; Amicosante, G.; Galleni, M.; Frère, J.-M.; Bush, K.; Rossolini, G.M. CAU-1, a subclass B3 metallo-β-lactamase of low substrate affinity encoded by an ortholog present in the Caulobacter crescentus chromosome. Antimicrob. Agents Chemother. 2002, 46, 1823–1830. [CrossRef] [PubMed]
Docquier, J.-D.; Lamotte-Brasseur, J.; Galleni, M.; Amicosante, G.; Frère, J.-M.; Rossolini, G.M. On functional and structural heterogeneity of VIM-type metallo-β-lactamases. J. Antimicrob. Chemother. 2003, 51, 257–266. [CrossRef] [PubMed]
Hernandez-Villadares, M.; Galleni, M.; Frère, J.-M.; Felici, A.; Perilli, M.; Franceschini, N.; Rossolini, G.M.; Oratore, A.; Amicosante, G. Overproduction and purification of the Aeromonas hydrophila CphA metallo-β-lactamse expressed in Escherichia coli. Microb. Drug Resist. 1996, 2, 253–256. [CrossRef]
Bebrone, C.; Anne, C.; De Vriendt, K.; Devreese, B.; Rossolini, G.M.; Van Beeumen, J.; Frère, J.-M.; Galleni, M. Dramatic broadening of the substrate profile of the Aeromonas hydrophila CphA metallo-β-lactamase by site-directed mutagenesis. J. Biol. Chem. 2005, 280, 28195–28202. [CrossRef]
Borgianni, L.; Vandenameele, J.; Matagne, A.; Bini, L.; Bonomo, R.; Frère, J.-M.; Rossolini, G.M.; Docquier, J.-D. Mutational analysis of VIM-2 reveals an essential determinant for metallo-β-lactamase stability and folding. Antimicrob. Agents Chemother. 2010, 54, 3197–3204. [CrossRef] [PubMed]
Yang, S.; Clayton, S.R.; Zechiedrich, E.L. Relative contributions of the AcrAB, MdfA and NorE efflux pumps to quinolone resistance in Escherichia coli. J. Antimicrob. Chemother. 2003, 51, 545–556. [CrossRef] [PubMed]
Sanner, M.F. Python: A programming language for software integration and development. J. Mol. Graph. Mod. 1999, 17, 57–61.
Brindisi, M.; Brogi, S.; Giovani, S.; Gemma, S.; Lamponi, S.; Luca, F.D.; Novellino, E.; Campiani, G.; Docquier, J.-D.; Butini, S. Targeting clinically-relevant metallo-β-lactamases: From high-throughput docking to broad-spectrum inhibitors. J. Enzyme Inhib. Med. Chem. 2016, 31, 98–109. [CrossRef] [PubMed]
Lassaux, P.; Traoré, D.A.K.; Loisel, E.; Favier, A.; Docquier, J.-D.; Sohier, J.-S.; Laurent, C.; Bebrone, C.; Frère, J.-M.; Ferrer, J.-L.; et al. Biochemical and structural characterization of the subclass B1 metallo-β-lactamase VIM-4. Antimicrob. Agents Chemother. 2011, 55, 1248–1255. [CrossRef]
Moali, C.; Anne, C.; Lamotte-Brasseur, J.; Groslambert, S.; Devreese, B.; Van Beeumen, J.; Galleni, M.; Frère, J.-M. Analysis of the importance of the metallo-β-lactamase active site loop in substrate binding and catalysis. Chem. Biol. 2003, 10, 319–329. [CrossRef]
Freire, E. Do enthalpy and entropy distinguish first class from best in class? Drug Discov. Today 2008, 13, 869–874. [CrossRef]
Ladbury, J.E. Calorimetry as a tool for understanding biomolecular interactions and an aid to drug design. Biochem. Soc. Trans. 2010, 38, 888–893. [CrossRef]
Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera-A visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605–1612. [CrossRef]
Vella, P.; Hussein, W.M.; Leung, E.W.; Clayton, D.; Ollis, D.L.; Mitić, N.; Schenk, G.; McGeary, R.P. The identification of new metallo-β-lactamase inhibitor leads from fragment-based screening. Bioorg. Med. Chem. Lett. 2011, 21, 3282–3285. [CrossRef] [PubMed]
Christopeit, T.; Carlsen, T.J.; Helland, R.; Leiros, H.K. Discovery of novel inhibitor scaffolds against the metallo-β-lactamase VIM-2 by surface plasmon resonance (SPR) based fragment screening. J. Med. Chem. 2015, 58, 8671–8682. [CrossRef] [PubMed]
Spyrakis, F.; Celenza, G.; Marcoccia, F.; Santucci, M.; Cross, S.; Bellio, P.; Cendron, L.; Perilli, M.; Tondi, D. Structure-based virtual screening for the discovery of novel inhibitors of New Delhi Metallo-β-lactamase-1. ACS Med. Chem. Lett. 2018, 9, 45–50. [CrossRef]
Faridoon; Hussein, W.M.; Vella, P.; Ul Islam, N.; Ollis, D.L.; Schenk, G.; McGeary, R.P. 3-Mercapto-1,2,4-triazoles and N-acylated thiosemicarbazides as metallo-β-lactamase inhibitors. Bioorg. Med. Chem. Lett. 2012, 22, 383–386. [CrossRef]
Feng, L.; Yang, K.-W.; Zhou, L.-S.; Xiao, J.-M.; Yang, X.; Zhai, L.; Zhang, Y.-L.; Crowder, M.W. N-Heterocyclic dicarboxylic acids: Broad-spectrum inhibitors of metallo-β-lactamases with co-antibacterial effect against antibiotic-resistant bacteria. Bioorg. Med. Chem. Lett. 2012, 22, 5185–5189. [CrossRef] [PubMed]
Linciano, P.; Gianquinto, E.; Montanari, M.; Maso, L.; Bellio, P.; Cebrian-Sastre, E.; Celenza, G.; Blazquez, J.; Cendron, L.; Spyrakis, F.; et al. 4-Amino-1,2,4-triazole-3-thione as a promising scaffold for the inhibition of serine and metallo-β-lactamases. Pharmaceuticals 2020, 13, 52. [CrossRef] [PubMed]
Christopeit, T.; Yang, K.-W.; Yang, S.-K.; Leiros, H.K. The structure of the metallo-β-lactamase VIM-2 in complex with a triazolylthioacetamide inhibitor. Acta Cryst. 2016, 72, 813–819. [CrossRef]
